Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?

Introduction Treatment options for metastatic renal cell carcinoma disease have been improved in recent years. However, there is still no optimal treatment sequence or combination for metastatic disease. We aimed to investigate whether patients differed in terms of disease outcomes regarding pre-niv...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cureus
Päätekijät: Ucar, Gokhan, Acikgoz, Yusuf, Ergun, Yakup, Bal, Oznur, Yilmaz, Mesut, Karakaya, Serdar, Akdeniz, Nadiye, Kostek, Osman, Aydin Isak, Ozlem, Yazici Sener, Gorkem, Dirikoc, Merve, Aktürk Esen, Selin, Dogan, Mutlu, Uncu, Dogan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Cureus 2020
Aiheet:
Radiation Oncology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7574822/
https://ncbi.nlm.nih.gov/pubmed/33094066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.10525
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia